NIH Funding Opportunities

Subscribe to NIH Funding Opportunities feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 3 hours 54 min ago

Comparative Effectiveness Research in Clinical Neurosciences (UG3/UH3 Clinical Trial Not Allowed)

Mon, 01/28/2019 - 07:29
Funding Opportunity PAR-19-171 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). Studies proposed should provide a cost-effective means of collecting data with a meaningful bearing on current clinical practice. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a observational study phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for observational studies will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of data collection, storage, and planned analyses. Operational planning activities include, at a minimum, development of recruitment and retention strategies, case report forms, data management system and other tools for data and quality management. The UH3 phase of the award will support the conduct of investigator-initiated observational study.
Categories: Science RSS Feeds

Notice of Request for Information to Better Facilitate Cancer Systems Epidemiology Research

Mon, 01/28/2019 - 00:49
Notice NOT-CA-19-019 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Limited Competition for a Connectome Coordination Facility (R24 Clinical Trial Not Allowed)

Fri, 01/25/2019 - 10:08
Funding Opportunity RFA-MH-20-210 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application to continue a Connectome Coordination Facility.The competition is limited to the R24 awardee of RFA-MH-15-750.The goal of this award is to (1) maintain a central data repository for Human Connectome data; (2) provide a helpdesk service to answer questions from investigators who are trying to collect data that are compatible with the existing Human Connectome data; and (3) to serve, in a limited capacity, to check quality control and harmonize data from existing Connectome awardees.
Categories: Science RSS Feeds

NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)

Fri, 01/25/2019 - 09:36
Funding Opportunity RFA-HL-20-012 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).
Categories: Science RSS Feeds

NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)

Fri, 01/25/2019 - 09:36
Funding Opportunity RFA-HL-20-011 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).
Categories: Science RSS Feeds

Request for Information (RFI): Soliciting Additional Input to the NIH 2018 Tribal Consultation on the Opioid Crisis in Indian Country

Fri, 01/25/2019 - 07:56
Notice NOT-OD-19-059 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Biology of Bladder Cancer (R21 Clinical Trial Optional)

Thu, 01/24/2019 - 10:14
Funding Opportunity PAR-19-169 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Categories: Science RSS Feeds

Biology of Bladder Cancer (R01 Clinical Trial Optional)

Thu, 01/24/2019 - 10:14
Funding Opportunity PAR-19-168 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Categories: Science RSS Feeds

Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

Thu, 01/24/2019 - 09:51
Funding Opportunity RFA-CA-19-032 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS) through research directed at addressing one of several proposed "Provocative Questions" (PQs). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention. Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.
Categories: Science RSS Feeds

HIV Vaccines Clinical Trials Network Leadership and Operations Center (UM1 Clinical Trial Required)

Thu, 01/24/2019 - 09:05
Funding Opportunity RFA-AI-19-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV Vaccines Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV Vaccines Clinical Trials Network.
Categories: Science RSS Feeds

HIV/AIDS Clinical Trials Networks Laboratory Centers (UM1 Clinical Trial Required)

Thu, 01/24/2019 - 09:05
Funding Opportunity RFA-AI-19-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for HIV/AIDS Clinical Trials Networks Laboratory Centers (LCs). Each LC will be responsible for providing a framework for laboratory leadership, structure and activities that contribute to the development and execution of the laboratory elements of NIAID HIV/AIDS Clinical Trials Networks research agendas.
Categories: Science RSS Feeds

Pages